Covariable | Distant disease-free survivalHR (95% CI) | P |
---|---|---|
CXCL13 expression | ||
 ≤ Median | ref. |  |
 > Median | 0.44 (0.29–0.67) | < 0.001 |
FOXP3 expression | ||
  ≤ Median | ref. | 0.400 |
 > Median | 1.20 (0.78–1.84) |  |
CD4 expression | ||
  ≤ Median | ref. | 0.396 |
 > Median | 1.89 (0.80–1.78) |  |
Age at study entry | ||
 ≤50 years | Ref. | 0.516 |
 >50 years | 0.88 (0.62–1.27) |  |
Tumor size | Â | 0.105 |
 pT1 | Ref. |  |
 pT2 | 1.22 (0.82–1.81) | 0.330 |
 pT3 | 1.89 (1.05–3.40) | 0.034 |
Axillary nodal status | Â | < 0.001 |
 pN0 | Ref. |  |
 pN1 | 4.51 (1.94–10.52) | < 0.001 |
 pN2 | 14.27 (4.78–42.71) | < 0.001 |
Histological grade | Â | 0.229 |
 I | Ref. |  |
 II | 2.06 (0.86–4.95) | 0.105 |
 III | 2.22 (0.88–5.52) | 0.088 |
Molecular subtype | Â | < 0.001 |
 Luminal A-like | Ref. |  |
 Luminal B-like | 1.79 (1.01–3.14) | 0.045 |
 Triple-negative | 4.18 (2.30–7.59) | < 0.001 |
 HER2-positive | 2.71 (1.56–4.68) | < 0.001 |